Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine
July 12 2021 - 9:44AM
Business Wire
Delivery to begin in the first quarter of
2022
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced a
supply agreement with the government of Argentina for 20 million
doses of Moderna’s COVID-19 vaccine or its updated variant booster
vaccine candidate, if authorized, to begin delivery in the first
quarter of 2022.
“We appreciate the support from the government of Argentina with
this supply agreement for doses of the Moderna COVID-19 vaccine or
our variant booster candidates,” said Stéphane Bancel, Chief
Executive Officer of Moderna. “We are committed to making our
vaccine available around the world as we seek to address the
pandemic with our COVID-19 vaccine.”
About the COVID-19 Vaccine Moderna
The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19
encoding for a prefusion stabilized form of the Spike (S) protein.
Moderna has received emergency (or other conditional, interim or
provisional) authorization for use of its COVID-19 vaccine in
adults from health agencies in more than 50 countries and an
Emergency Use Listing (EUL) from the World Health Organization
(WHO). Moderna has filed for emergency (or other conditional,
interim or provisional) authorization for use of its COVID-19
vaccine in adolescents with global health agencies.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed. Moderna maintains alliances with
a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both
groundbreaking science and rapid scaling of manufacturing. Most
recently, Moderna’s capabilities have come together to allow the
authorized use of one of the earliest and most-effective vaccines
against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Today, 24 development programs
are underway across these therapeutic areas, with 15 programs
having entered the clinic. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the Company’s development of
a vaccine to protect against the SARS-CoV-2 virus (mRNA-1273, also
referred to as COVID-19 Vaccine Moderna and the Moderna COVID-19
Vaccine), as well as booster vaccine candidates; the Company’s
agreement to supply the vaccine to the government of Argentina; and
the anticipated number of doses and timing for delivery of vaccine
supply. The forward-looking statements in this press release are
neither promises nor guarantees, and you should not place undue
reliance on these forward-looking statements because they involve
known and unknown risks, uncertainties, and other factors, many of
which are beyond Moderna’s control and which could cause actual
results to differ materially from those expressed or implied by
these forward-looking statements. These risks, uncertainties, and
other factors include those other risks and uncertainties described
under the heading “Risk Factors” in Moderna’s most recent Annual
Report on Form 10-K filed with the U.S. Securities and Exchange
Commission (SEC) and in subsequent filings made by Moderna with the
SEC, which are available on the SEC’s website at www.sec.gov.
Except as required by law, Moderna disclaims any intention or
responsibility for updating or revising any forward-looking
statements contained in this press release in the event of new
information, future developments or otherwise. These
forward-looking statements are based on Moderna’s current
expectations and speak only as of the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210712005515/en/
Moderna Contacts Media: Colleen Hussey Director,
Corporate Communications 617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Senior Vice President & Head
of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024